JW Pharmaceutical Future Growth

Future criteria checks 3/6

JW Pharmaceutical is forecast to grow earnings and revenue by 29.1% and 8.6% per annum respectively. EPS is expected to grow by 48.2% per annum. Return on equity is forecast to be 18.1% in 3 years.

Key information

29.1%

Earnings growth rate

48.2%

EPS growth rate

Pharmaceuticals earnings growth	33.8%
Revenue growth rate	8.6%
Future return on equity	18.1%
Analyst coverage	Low
Last updated	15 Feb 2024

Recent future growth updates

Recent updates

JW Pharmaceutical's(KRX:001060) Share Price Is Down 24% Over The Past Three Years.

Jan 19

Do These 3 Checks Before Buying JW Pharmaceutical Corporation (KRX:001060) For Its Upcoming Dividend

Dec 24

Would JW Pharmaceutical Corporation (KRX:001060) Be Valuable To Income Investors?

Nov 30

Earnings and Revenue Growth Forecasts

KOSE:A001060 - Analysts future estimates and past financials data (KRW Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	889,967	72,500	33,400	88,950	3
12/31/2024	827,467	73,500	35,250	95,600	3
12/31/2023	748,527	37,006	46,452	87,157	N/A
9/30/2023	736,668	24,614	42,709	76,046	N/A
6/30/2023	722,312	50,572	29,078	58,339	N/A
3/31/2023	701,393	37,309	28,177	51,238	N/A
12/31/2022	684,351	31,892	44,412	56,764	N/A
9/30/2022	660,661	12,130	32,649	46,346	N/A
6/30/2022	639,806	8,930	37,194	50,657	N/A
3/31/2022	620,832	4,584	27,866	41,446	N/A
12/31/2021	606,585	-968	5,222	18,124	N/A
9/30/2021	581,827	-1,190	4,847	19,302	N/A
6/30/2021	569,978	-3,329	22,689	36,349	N/A
3/31/2021	560,407	-8,469	28,086	43,146	N/A
12/31/2020	547,336	-15,241	48,015	63,054	N/A
9/30/2020	516,529	-31,512	65,219	77,881	N/A
6/30/2020	512,402	-33,320	36,132	49,800	N/A
3/31/2020	510,079	-23,341	43,389	56,719	N/A
12/31/2019	511,335	-25,275	42,354	55,531	N/A
9/30/2019	524,767	-9,432	3,533	16,086	N/A
6/30/2019	538,269	-8,270	40,264	51,987	N/A
3/31/2019	536,808	-659	61,987	72,856	N/A
12/31/2018	537,182	8,057	42,829	52,110	N/A
9/30/2018	534,919	9,113	56,378	66,480	N/A
6/30/2018	521,666	12,567	27,538	35,484	N/A
3/31/2018	510,284	2,417	-3,936	5,770	N/A
12/31/2017	502,919	-742	23,470	33,450	N/A
9/30/2017	490,656	14,223	N/A	36,480	N/A
6/30/2017	476,290	3,697	N/A	6,678	N/A
3/31/2017	471,517	-11,472	N/A	14,991	N/A
12/31/2016	467,465	-10,934	N/A	6,739	N/A
9/30/2016	460,523	-18,836	N/A	-799	N/A
6/30/2016	452,150	-12,991	N/A	17,745	N/A
3/31/2016	447,417	2,860	N/A	28,884	N/A
12/31/2015	434,352	1,921	N/A	-4,175	N/A
9/30/2015	447,788	1,575	N/A	8,860	N/A
6/30/2015	439,802	1,064	N/A	15,286	N/A
3/31/2015	426,011	-3,378	N/A	-12,885	N/A
12/31/2014	412,791	-2,357	N/A	7,279	N/A
9/30/2014	386,064	-2,651	N/A	6,994	N/A
6/30/2014	386,067	-2,648	N/A	-16,031	N/A
3/31/2014	395,535	3,095	N/A	16,653	N/A
12/31/2013	394,182	2,275	N/A	18,725	N/A
9/30/2013	401,971	-6,575	N/A	2,775	N/A
6/30/2013	397,590	-9,125	N/A	9,541	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A001060's forecast earnings growth (29.1% per year) is above the savings rate (2.5%).

Earnings vs Market: A001060's earnings (29.1% per year) are forecast to grow faster than the KR market (28.4% per year).

High Growth Earnings: A001060's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: A001060's revenue (8.6% per year) is forecast to grow slower than the KR market (9.1% per year).

High Growth Revenue: A001060's revenue (8.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: A001060's Return on Equity is forecast to be low in 3 years time (18.1%).

JW Pharmaceutical Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Price target increased by 22% to ₩40,163

Price target increased by 7.7% to ₩36,245

Price target decreased to ₩33,000

Price target increased to ₩40,000

Recent updates

Now 21% overvalued

JW Pharmaceutical's (KRX:001060) Earnings Are Of Questionable Quality

Full year 2023 earnings: EPS misses analyst expectations

Now 21% overvalued after recent price rise

Price target increased by 22% to ₩40,163

Investor sentiment improves as stock rises 17%

New minor risk - Earnings quality

Investor sentiment improves as stock rises 21%

New minor risk - Shareholder dilution

Investor sentiment deteriorates as stock falls 18%

Now 21% undervalued

Investor sentiment improves as stock rises 19%

Price target increased by 7.7% to ₩36,245

New minor risk - Share price stability

Investor sentiment improves as stock rises 24%

Full year 2022 earnings released: EPS: ₩1,331 (vs ₩41.00 loss in FY 2021)

Upcoming dividend of ₩375 per share

No independent directors

Price target decreased to ₩33,000

Price target increased to ₩40,000

No independent directors

Upcoming dividend of ₩316 per share

Is JW Pharmaceutical Corporation (KRX:001060) An Attractive Dividend Stock?

Full year 2020 earnings released: ₩676 loss per share (vs ₩1,158 loss in FY 2019)

How Many JW Pharmaceutical Corporation (KRX:001060) Shares Do Institutions Own?

Is JW Pharmaceutical (KRX:001060) Using Too Much Debt?

JW Pharmaceutical Corporation, Annual General Meeting, Mar 26, 2021

New 90-day low: ₩30,550

JW Pharmaceutical's(KRX:001060) Share Price Is Down 24% Over The Past Three Years.

New 90-day high: ₩36,200

Do These 3 Checks Before Buying JW Pharmaceutical Corporation (KRX:001060) For Its Upcoming Dividend

New 90-day high: ₩36,500

Would JW Pharmaceutical Corporation (KRX:001060) Be Valuable To Income Investors?

Third quarter 2020 earnings released: EPS ₩134

New 90-day low: ₩31,950

New 90-day high: ₩40,800

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies